The Health Department this
morning released the final report
from the Independent Review of
Medicines and Medicinal Devices
Regulation, which “highlights
the importance of cutting red
tape for the rapidly expanding
complementary medicines sector”.
The review was undertaken by
Lloyd Sansom, Will Delaat and
John Horvath, and makes 26
recommendations.
The panel has suggested that S3
advertising guidelines be reviewed
to provide for a formal risk-benefit
methodology for inclusion in
Appendix H, and also recommends
that the process of pre-approval
of the advertising of therapeutic
goods be replaced by a “more self-regulatory
regime”.
See health.gov.au for the report.The above article was sent to subscribers in Pharmacy Daily's issue from 20 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Nov 15
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
AUSTRALIA’S public hospitals are facing their lengthiest wait times on record for planned surgeries, with emergency departments struggling under access blockages, according to the latest annual Public Hospital Report Card by the Australian Medical Association (AMA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.